Soleno Therapeutics Inc
Biotechnology · Healthcare
CFO
2020-11-11–2026-02-26
James Mackaness
Equibles does not estimate personal net worth.
About James Mackaness
Earlier roles on record: CFO at Soleno Therapeutics Inc until February 26, 2026. Soleno Therapeutics Inc reported in an 8-K filed February 26, 2026 that James Mackaness retired as Chief Financial Officer. The proxy statement of Soleno Therapeutics Inc reports total compensation of $8,774,955 for James Mackaness in fiscal 2024, including a base salary of $460,000. Disclosed compensation is on record for 4 fiscal years.
“Mrs. Fulk will succeed the Company's current Chief Financial Officer, James Mackaness, who announced that he intends to retire by the end of March.”
Affiliation history
-
Soleno Therapeutics Inc
CFO
SEC 8-K
2020-11-11–2026-02-26
Company network
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Soleno Therapeutics Inc | Chief Financial Officer | $460,000 | $8,774,955 |
| 2023 | Soleno Therapeutics Inc | Chief Financial Officer | $400,000 | $1,211,636 |
| 2022 | Soleno Therapeutics Inc | Chief Financial Officer | $385,000 | $626,195 |
| 2020 | Soleno Therapeutics Inc | Chief Financial Officer | $198,988 | $710,468 |